IMVT vs XNCR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMVT Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunovant, Inc. Common Stock (IMVT) driven by superior Growth & Margin, Options & Structure while XNCR counters with relative strength in Valuation, Momentum & Technical. Fundamentally, IMVT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus XNCR at 68.0x Forward P/E and -72.7% operating margin (+454.9% YoY). In options structure, IMVT sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against XNCR sits in BREAKOUT (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IMVT | XNCR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.3B | $2.9B | Larger Scale | IMVT |
| Trailing P/E Ratio Valuation | N/M | 68.0x | Lower Multiple | XNCR |
| Forward P/E Ratio Valuation | N/M | 68.0x | Lower Multiple | XNCR |
| Revenue Growth (YoY) Growth | +0.0% | +454.9% | Higher Growth | XNCR |
| Operating Margin (TTM) Profitability | 0.0% | -72.7% | Higher Margin | IMVT |
| Net Profit Margin Profitability | 0.0% | -58.8% | Higher Margin | IMVT |
| Return on Equity (ROE) Capital Efficiency | -86.5% | -19.9% | Higher ROE | XNCR |
| 52-Week Range Position Momentum | 49% ($22โ$45) | 84% ($10โ$41) | Stronger Trend | XNCR |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 72% Vol | 1.21ฮฒ ยท 87% Vol | Lower Realized Risk | IMVT |
| Unified Institutional Score Composite Signal | 39.6 / 100 (SELL) | 29.6 / 100 (SELL) | Higher Composite | IMVT |